Compare WST & CBOE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WST | CBOE |
|---|---|---|
| Founded | 1923 | 1973 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.9B | 26.8B |
| IPO Year | 2004 | 2010 |
| Metric | WST | CBOE |
|---|---|---|
| Price | $236.29 | $283.19 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 7 | 9 |
| Target Price | ★ $319.43 | $271.00 |
| AVG Volume (30 Days) | 709.0K | ★ 793.3K |
| Earning Date | 04-23-2026 | 05-01-2026 |
| Dividend Yield | 0.37% | ★ 1.01% |
| EPS Growth | 1.49 | ★ 44.52 |
| EPS | 6.79 | ★ 10.42 |
| Revenue | ★ $2,886,900,000.00 | $2,229,100,000.00 |
| Revenue This Year | $6.73 | N/A |
| Revenue Next Year | $6.07 | $4.68 |
| P/E Ratio | $35.52 | ★ $27.30 |
| Revenue Growth | 1.95 | ★ 239.31 |
| 52 Week Low | $187.43 | $200.88 |
| 52 Week High | $322.34 | $305.68 |
| Indicator | WST | CBOE |
|---|---|---|
| Relative Strength Index (RSI) | 44.07 | 46.48 |
| Support Level | $230.42 | $279.05 |
| Resistance Level | $251.73 | $305.68 |
| Average True Range (ATR) | 6.78 | 6.76 |
| MACD | -0.15 | -2.16 |
| Stochastic Oscillator | 27.48 | 19.15 |
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.
Founded in 1973, Cboe controls the largest option exchange in the US, which provides around 60% of the firm's revenue. The company is best known for its proprietary S&P 500 and VIX index options, which it offers through an exclusive contract with S&P Global. The firm moved into US and European equities through the $3.4 billion acquisition of BATS in 2017. Cboe has continued to look to expand internationally, using acquisitions to build a presence in both Canada and Australia.